TNYA |
Tenaya Therapeutics, Inc. |
Oct 18, 2024 |
1 |
$0 |
4 |
Oct 21, 2024 |
Director |
RARE |
Ultragenyx Pharmaceutical Inc. |
Jun 12, 2024 |
1 |
-$441K |
4 |
Jun 12, 2024 |
EVP and Chief Legal Officer |
RARE |
Ultragenyx Pharmaceutical Inc. |
Mar 1, 2024 |
4 |
-$202K |
4 |
Mar 5, 2024 |
EVP and Chief Legal Officer |
EOLS |
Evolus, Inc. |
Feb 7, 2024 |
2 |
$0 |
4 |
Feb 9, 2024 |
Director |
EOLS |
Evolus, Inc. |
Jan 30, 2024 |
1 |
-$157K |
4 |
Feb 2, 2024 |
Director |
TNYA |
Tenaya Therapeutics, Inc. |
Jun 9, 2023 |
1 |
$0 |
4 |
Jun 12, 2023 |
Director |
RARE |
Ultragenyx Pharmaceutical Inc. |
May 4, 2023 |
1 |
-$197K |
4 |
May 5, 2023 |
EVP and Chief Legal Officer |
RARE |
Ultragenyx Pharmaceutical Inc. |
Mar 1, 2023 |
4 |
-$143K |
4 |
Mar 3, 2023 |
EVP and Chief Legal Officer |
EOLS |
Evolus, Inc. |
Jan 27, 2023 |
2 |
$0 |
4 |
Jan 31, 2023 |
Director |
TNYA |
Tenaya Therapeutics, Inc. |
Sep 8, 2022 |
1 |
$0 |
4 |
Sep 9, 2022 |
Director |
ANEB |
Anebulo Pharmaceuticals, Inc. |
Apr 21, 2022 |
1 |
$0 |
4 |
Oct 3, 2022 |
Director |
RARE |
Ultragenyx Pharmaceutical Inc. |
Mar 7, 2022 |
1 |
-$324K |
4 |
Mar 8, 2022 |
EVP and Chief Legal Officer |
RARE |
Ultragenyx Pharmaceutical Inc. |
Mar 1, 2022 |
3 |
-$192K |
4 |
Mar 3, 2022 |
EVP and Chief Legal Officer |
EOLS |
Evolus, Inc. |
Jan 24, 2022 |
2 |
$0 |
4 |
Jan 26, 2022 |
Director |
TNYA |
Tenaya Therapeutics, Inc. |
Dec 22, 2021 |
1 |
$0 |
4 |
Dec 23, 2021 |
Director |
TNYA |
Tenaya Therapeutics, Inc. |
Dec 22, 2021 |
0 |
$0 |
3 |
Dec 23, 2021 |
Director |
RARE |
Ultragenyx Pharmaceutical Inc. |
Oct 14, 2021 |
1 |
-$25.2K |
4 |
Oct 18, 2021 |
EVP and General Counsel |
RARE |
Ultragenyx Pharmaceutical Inc. |
Sep 8, 2021 |
3 |
-$339K |
4 |
Sep 9, 2021 |
EVP and General Counsel |
ARCT |
Arcturus Therapeutics Holdings Inc. |
Jun 18, 2021 |
1 |
$0 |
4 |
Jun 22, 2021 |
Director |
RARE |
Ultragenyx Pharmaceutical Inc. |
Jun 10, 2021 |
1 |
-$133K |
4 |
Jun 11, 2021 |
EVP and General Counsel |
RARE |
Ultragenyx Pharmaceutical Inc. |
May 6, 2021 |
1 |
-$35.6K |
4 |
May 10, 2021 |
EVP and General Counsel |